Free tool
FAERS Monitor: Indocin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018332 or its brand name (Indocin, Indomethacin). Reports on generic versions are filed under their own applications.
Reports
13,296
Serious
10,490
79% of reports
Hospitalization
4,486
Death reported
1,529
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,432
- fatigue1,151
- headache1,058
- arthralgia1,036
- off label use1,027
- nausea949
- pain944
- diarrhoea906
- dizziness894
- dyspnoea770
- vomiting760
- asthenia658
- pyrexia631
- pruritus625
- malaise619
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 358 |
| 2005 | 372 |
| 2006 | 391 |
| 2007 | 385 |
| 2008 | 356 |
| 2009 | 408 |
| 2010 | 374 |
| 2011 | 486 |
| 2012 | 702 |
| 2013 | 430 |
| 2014 | 395 |
| 2015 | 555 |
| 2016 | 681 |
| 2017 | 592 |
| 2018 | 740 |
| 2019 | 820 |
| 2020 | 640 |
| 2021 | 755 |
| 2022 | 1,010 |
| 2023 | 867 |
| 2024 | 884 |
| 2025 | 742 |
| 2026 | 352 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,863 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| arthralgiaSignal | 1,036 | 3.9 | 3.7 | 2,319 |
| pyrexiaSignal | 631 | 2.9 | 2.7 | 789 |
| dizzinessSignal | 894 | 2.8 | 2.7 | 1,087 |
| astheniaSignal | 658 | 2.8 | 2.6 | 755 |
| headacheSignal | 1,058 | 2.7 | 2.5 | 1,138 |
| pruritusSignal | 625 | 2.6 | 2.4 | 611 |
| vomitingSignal | 760 | 2.6 | 2.4 | 736 |
| painSignal | 944 | 2.4 | 2.3 | 818 |
| fatigueSignal | 1,151 | 2.3 | 2.2 | 915 |
| malaiseSignal | 619 | 2.2 | 2.1 | 429 |
| diarrhoeaSignal | 906 | 2.2 | 2.1 | 626 |
| dyspnoeaSignal | 770 | 2.2 | 2.0 | 487 |
| nausea | 949 | 1.9 | 1.8 | 417 |
| off label use | 1,027 | 1.9 | 1.8 | 422 |
| drug ineffective | 1,432 | 1.7 | 1.6 | 459 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.